Skip to main content

$0.042 -0.001 (-2.33%)

High

$0.04

Low

$0.04

Trades

17

Turnover

$24,861

Volume

582,113
30 June 2023 at 3:56pm
Register to track ACR and receive email alerts.
Subject
ACR Ann: Updated Corporate Policy - Code of Conduct

ACR Ann: Appendix 3Y - Oldham

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Acrux announces commercial agreement with Padagis

ACR Ann: Successful patent litigation outcome

ACR Ann: Appendix 3Y - Brumley

ACR Ann: Appendix 3Y - Dobinson

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Appendix 3Y - Brumley

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Updated Continuous Disclosure & Shareholder Reporting Policy

ACR Ann: Updated Board Charter

ACR Ann: Appendix 3Y - Ross Dobinson

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Appendix 4D, Half Year Accounts as at 31 December 2021

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Notification regarding unquoted securities - ACR

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Securities Trading Policy

ACR Ann: Whistleblower Policy

ACR Ann: Appendix 3Y Brumley

ACR Ann: Appendix 3Y Kotsanis

ACR Ann: Appendix 3Y Brumley

ACR Ann: Notification regarding unquoted securities - ACR

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Amendment to Constitution

ACR Ann: Results of Annual General Meeting

ACR Ann: Annual General Meeting Presentation and Addresses

ACR Ann: R&D Tax Incentive Rebate received

ACR Ann: Anti-Bribery, Corruption and Fraud Policy

ACR Ann: JobKeeper disclosure

ACR Ann: Annual Report to shareholders

ACR Ann: Notice of Annual General Meeting/Proxy Form

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Acrux and Harris terminate license agreement

ACR Ann: Annual General meeting and date for director nominations

ACR Ann: Appendix 3Y - Ross Dobinson

ACR Ann: Application for quotation of securities - ACR

ACR Ann: Acrux's fifth generic dossier accepted by FDA for review

ACR Ann: Acrux Investor Presentation - September 2021

ACR Ann: US Launch - Testosterone Topical Solution

ACR Ann: Appendix 4G and Corporate Governance Statement

ACR Ann: Appendix 4E and Financial Report

ACR Ann: Acrux receives third FDA ANDA approval

ACR Ann: Notification of cessation of securities - ACR

ACR Ann: Audit and Risk Committee Charter

ACR Ann: Human Capital and Nomination Committee Charter

ACR Ann: Code of Conduct

Register to track ACR and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL